The announcement of positive preliminary clinical data is generally perceived as a positive development for biotech companies. This can lead to increased investor confidence and a potential rise in stock prices. Given that the news directly pertains to Revolution Medicines, the relevance is high. The importance is also significant as clinical data can greatly influence a biotech company's stock price.